GlycoFlux™ AAV1-Human PYGL Viral Particle

GlycoFlux™ AAV1-PYGL Viral Particle drives stable PYGL (liver glycogen phosphorylase) expression to release glucose-1-phosphate from hepatic glycogen with Ser15 phosphorylation and allosteric control, and this product preferentially targets liver, pancreas, and heart to support chronic glycemia and glycogenolysis studies for research use only.

Recombinant AAV1

PYGL

Human

CMV, CAG, TRE, or other promoters

Smooth muscle, Central Nervous System (CNS), Retina, Pancreas, Inner Ear, Heart, Liver

AAV Triple-Plasmid Transfection System

HEK293T

This AAV1 viral particle is primarily used for overexpressing target genes in muscle tissues (smooth muscle, heart) and the central nervous system (CNS) / sensory organs (retina, inner ear). It is an ideal tool for research and pre-clinical studies focused on myopathies, cardiac disorders, and certain neurological or sensory genetic diseases.

Shipped on dry ice, with temperature maintained at ≤ -80°C.

Store at -80°C to preserve viral titer and stability.

Store this product at -80°C and minimize freeze-thaw cycles to preserve viral titer. For safety, handle in a certified biological safety cabinet and wear appropriate PPE (lab coat, gloves, and eye protection).

This product is intended for research use only and is not approved for diagnostic procedures or clinical applications. Users are solely responsible for implementing appropriate safety practices and complying with all applicable laws, regulations, and institutional policies. While Creative Biolabs is committed to rigorous quality control, no guarantee is made regarding performance in any particular assay or application.

qPCR/TCID50

No mycoplasma contamination was detected.

Sterility testing verified the absence of microbial contamination.

Upon request, Creative Biolabs performs in vitro or in vivo transduction assays to assess AAV delivery to target cells and to quantify transgene expression and function.

All AAV preparations from Creative Biolabs are verified for vector-genome identity by PCR. In this assay, target cells are transduced with serial dilutions of the AAV preparation, harvested after a short incubation, and genomic DNA is isolated; a defined region of the packaged transgene is then PCR-amplified to confirm the expected sequence.

Glycogen Phosphorylase L

GSD6

14q22.1

This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1,4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms.